JP2022500448A - 制御性ｔ細胞を調節し腫瘍増殖を阻害する方法 - Google Patents

制御性ｔ細胞を調節し腫瘍増殖を阻害する方法 Download PDF

Info

Publication number
JP2022500448A
JP2022500448A JP2021514336A JP2021514336A JP2022500448A JP 2022500448 A JP2022500448 A JP 2022500448A JP 2021514336 A JP2021514336 A JP 2021514336A JP 2021514336 A JP2021514336 A JP 2021514336A JP 2022500448 A JP2022500448 A JP 2022500448A
Authority
JP
Japan
Prior art keywords
cancer
cells
inhibitor
antibody
pparβ
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2021514336A
Other languages
English (en)
Japanese (ja)
Other versions
JPWO2020053833A5 (https=
JP2022500448A5 (https=
Inventor
ピン−チー ホ
ハイピン ワン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Universite de Lausanne
Original Assignee
Universite de Lausanne
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Universite de Lausanne filed Critical Universite de Lausanne
Publication of JP2022500448A publication Critical patent/JP2022500448A/ja
Publication of JPWO2020053833A5 publication Critical patent/JPWO2020053833A5/ja
Publication of JP2022500448A5 publication Critical patent/JP2022500448A5/ja
Priority to JP2024124104A priority Critical patent/JP2024153816A/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001102—Receptors, cell surface antigens or cell surface determinants
    • A61K39/001129—Molecules with a "CD" designation not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Endocrinology (AREA)
  • Cell Biology (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2021514336A 2018-09-14 2019-09-13 制御性ｔ細胞を調節し腫瘍増殖を阻害する方法 Pending JP2022500448A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024124104A JP2024153816A (ja) 2018-09-14 2024-07-31 制御性ｔ細胞を調節し腫瘍増殖を阻害する方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862731351P 2018-09-14 2018-09-14
US62/731,351 2018-09-14
PCT/IB2019/057745 WO2020053833A1 (en) 2018-09-14 2019-09-13 Methods for modulating regulatory t cells and inhibiting tumor growth

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024124104A Division JP2024153816A (ja) 2018-09-14 2024-07-31 制御性ｔ細胞を調節し腫瘍増殖を阻害する方法

Publications (3)

Publication Number Publication Date
JP2022500448A true JP2022500448A (ja) 2022-01-04
JPWO2020053833A5 JPWO2020053833A5 (https=) 2022-08-29
JP2022500448A5 JP2022500448A5 (https=) 2022-08-29

Family

ID=68393033

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021514336A Pending JP2022500448A (ja) 2018-09-14 2019-09-13 制御性ｔ細胞を調節し腫瘍増殖を阻害する方法
JP2024124104A Pending JP2024153816A (ja) 2018-09-14 2024-07-31 制御性ｔ細胞を調節し腫瘍増殖を阻害する方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024124104A Pending JP2024153816A (ja) 2018-09-14 2024-07-31 制御性ｔ細胞を調節し腫瘍増殖を阻害する方法

Country Status (7)

Country Link
US (1) US20220049010A1 (https=)
EP (1) EP3849666B1 (https=)
JP (2) JP2022500448A (https=)
CN (2) CN121534175A (https=)
AU (2) AU2019340475B2 (https=)
CA (1) CA3109563A1 (https=)
WO (1) WO2020053833A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023512276A (ja) * 2020-01-30 2023-03-24 オーエヌエー セラピューティクス エセ．エレ． 癌及び癌転移の治療のための併用療法

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2990885A1 (en) 2015-06-30 2017-01-05 Sanford-Burnham Medical Research Institute Btla fusion protein agonists and uses thereof
CN112168820B (zh) * 2019-07-05 2023-09-29 中国科学院生物物理研究所 SRCAP ATPase抑制剂在结直肠癌治疗中的应用
GB202007099D0 (en) 2020-05-14 2020-07-01 Kymab Ltd Tumour biomarkers for immunotherapy

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2004509917A (ja) * 2000-09-27 2004-04-02 ティア、メディカ、アクチスカベット 増殖性皮膚疾患の治療のための脂肪酸類似体
JP2012149004A (ja) * 2011-01-18 2012-08-09 Theravalues Corp 核内受容体の賦活剤

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20070022197A (ko) * 2003-11-05 2007-02-26 팔링겐, 인코포레이티드 Ｃｄｉｍ 결합 항체의 증강된 ｂ 세포 세포독성
JP2008521814A (ja) * 2004-11-24 2008-06-26 シェーリング コーポレイション Ｄａｐ−１０およびその使用
CA2988119A1 (en) * 2015-06-03 2016-12-08 Dana-Farber Cancer Institute, Inc. Methods to induce conversion of regulatory t cells into effector t cells for cancer immunotherapy
EP3650468A1 (en) * 2015-09-29 2020-05-13 Fundació Institut de Recerca Biomèdica (IRB Barcelona) Targeting metastasis stem cells through a fatty acid receptor (cd36)
WO2018029336A1 (en) * 2016-08-12 2018-02-15 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for determining whether a subject was administered with an activator of the ppar beta/delta pathway.
GB201802307D0 (en) * 2018-02-13 2018-03-28 Vib Vzw CD36 antagonists for use in melanoma treatment

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2004509917A (ja) * 2000-09-27 2004-04-02 ティア、メディカ、アクチスカベット 増殖性皮膚疾患の治療のための脂肪酸類似体
JP2012149004A (ja) * 2011-01-18 2012-08-09 Theravalues Corp 核内受容体の賦活剤

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
IMMUNOLOGY, vol. 138, JPN6023030303, 2013, pages 105 - 115, ISSN: 0005111791 *
ONCOIMMUNOLOGY, vol. 6, no. 10, JPN6023030302, 2017, pages 1344804, ISSN: 0005293799 *
PING YANG; ET AL: "DIETARY OLEIC ACID-INDUCED CD36 PROMOTES CERVICAL CANCER CELL GROWTH AND METASTASIS 以下備考", CANCER LETTERS, vol. 438, JPN5021013027, 11 September 2018 (2018-09-11), pages 76 - 85, ISSN: 0005111792 *
X WANG; ET AL: "PPAR-DELTA PROMOTES SURVIVAL OF BREAST CANCER CELLS IN HARSH METABOLIC CONDITIONS", ONCOGENESIS, vol. 5, JPN5021013028, 2016, pages 232 - 1, ISSN: 0005111793 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023512276A (ja) * 2020-01-30 2023-03-24 オーエヌエー セラピューティクス エセ．エレ． 癌及び癌転移の治療のための併用療法

Also Published As

Publication number Publication date
AU2019340475A1 (en) 2021-03-11
JP2024153816A (ja) 2024-10-29
CN112703039A (zh) 2021-04-23
EP3849666A1 (en) 2021-07-21
WO2020053833A1 (en) 2020-03-19
CA3109563A1 (en) 2020-03-19
EP3849666B1 (en) 2026-04-15
US20220049010A1 (en) 2022-02-17
CN121534175A (zh) 2026-02-17
AU2019340475B2 (en) 2025-04-17
AU2025205589A1 (en) 2025-08-07

Similar Documents

Publication Publication Date Title
Bayati et al. The therapeutic potential of regulatory T cells: challenges and opportunities
US11207393B2 (en) Regulatory T cell PD-1 modulation for regulating T cell effector immune responses
Hatae et al. Enhancing CAR-T cell metabolism to overcome hypoxic conditions in the brain tumor microenvironment
JP2024153816A (ja) 制御性ｔ細胞を調節し腫瘍増殖を阻害する方法
US20190192565A1 (en) Methods to induce conversion of regulatory t cells into effector t cells for cancer immunotherapy
JP2020164539A (ja) 腫瘍免疫寛容を破綻させるためのｙａｐの阻害方法
Dwivedi et al. Implications of regulatory T cells in anti-cancer immunity: from pathogenesis to therapeutics
Lepez et al. Long-term T cell fitness and proliferation is driven by AMPK-dependent regulation of reactive oxygen species
JP2020507343A (ja) Ｎｋ細胞を活性化するための組成物及び方法
US20240262909A1 (en) Tim-3 modulates anti-tumor immunity by regulating inflammasome activation
US12312398B2 (en) Compositions and methods for targeting activin signaling to treat cancer
JP2019528288A (ja) がん免疫療法のための組成物および方法
JP2022512161A (ja) 免疫療法のための組成物及び方法
Zhai et al. Myeloid cells meet CD8+ T cell exhaustion in cancer: What, why and how
Tang et al. Anti-CD20 monoclonal antibody combined with adenovirus vector-mediated IL-10 regulates spleen CD4+/CD8+ T cells and T-bet/GATA-3 expression in NOD mice
Benito-Lopez et al. Partners in crime: the feedback loop between metabolic reprogramming and immune checkpoints in the tumor microenvironment
US20230127263A1 (en) Modified t cells and methods of preparing the same
HK40045698A (en) Methods for modulating regulatory t cells and inhibiting tumor growth
JP2017526702A (ja) ＰＰＡＲ−γアゴニストを投与する段階を含む、癌を治療する方法
US20240307497A1 (en) Adiponectin alone or in combination with extracorporeal photopheresis (ecp) for immune related adverse events of immune checkpoint inhibitors
Sippel Neutrophil activation induces peripheral immunosuppression in glioblastoma and stroke

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220819

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20220819

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20230704

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230724

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20231023

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240123

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20240401